Correlation Between Cymbria and Cardiol Therapeutics
Can any of the company-specific risk be diversified away by investing in both Cymbria and Cardiol Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cymbria and Cardiol Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cymbria and Cardiol Therapeutics Class, you can compare the effects of market volatilities on Cymbria and Cardiol Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cymbria with a short position of Cardiol Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cymbria and Cardiol Therapeutics.
Diversification Opportunities for Cymbria and Cardiol Therapeutics
-0.41 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Cymbria and Cardiol is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Cymbria and Cardiol Therapeutics Class in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cardiol Therapeutics and Cymbria is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cymbria are associated (or correlated) with Cardiol Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cardiol Therapeutics has no effect on the direction of Cymbria i.e., Cymbria and Cardiol Therapeutics go up and down completely randomly.
Pair Corralation between Cymbria and Cardiol Therapeutics
Assuming the 90 days trading horizon Cymbria is expected to generate 0.29 times more return on investment than Cardiol Therapeutics. However, Cymbria is 3.46 times less risky than Cardiol Therapeutics. It trades about 0.01 of its potential returns per unit of risk. Cardiol Therapeutics Class is currently generating about -0.16 per unit of risk. If you would invest 7,475 in Cymbria on September 2, 2024 and sell it today you would earn a total of 15.00 from holding Cymbria or generate 0.2% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Cymbria vs. Cardiol Therapeutics Class
Performance |
| Timeline |
| Cymbria |
| Cardiol Therapeutics |
Cymbria and Cardiol Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Cymbria and Cardiol Therapeutics
The main advantage of trading using opposite Cymbria and Cardiol Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cymbria position performs unexpectedly, Cardiol Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will offset losses from the drop in Cardiol Therapeutics' long position.| Cymbria vs. Clairvest Group | Cymbria vs. Uniteds Limited | Cymbria vs. E L Financial Corp | Cymbria vs. Senvest Capital |
| Cardiol Therapeutics vs. Medipharm Labs Corp | Cardiol Therapeutics vs. Avicanna | Cardiol Therapeutics vs. Medicenna Therapeutics Corp | Cardiol Therapeutics vs. Charlottes Web Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |